# Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

> **NCT00310375** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 181 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Ezogabine: USAN Retigabine (International Nonproprietary Name)

## Key facts

- **NCT ID:** NCT00310375
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-01
- **Primary completion:** 2016-11-30
- **Final completion:** 2017-03-15
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310375, "Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00310375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*